Editas Medicine prices $125M public offering of shares and warrants

Editas Medicine, Inc.

Priced 55,555,556 shares and warrants at $2.25 per unit; gross proceeds $125M before warrant exercise.
Warrants exercisable at $3.50/share, expire upon EDIT-401 Phase 1 data milestone or within 3 years.
If all warrants exercised, additional proceeds ~$194.4M; net proceeds estimated ~$117M.
Cash runway extended into second half of 2028 based on current plans.
Underwriters: Cantor Fitzgerald and Wells Fargo; closing expected May 27, 2026.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Editas Medicine, Inc. entered into Underwriting Agreement with Cantor Fitzgerald & Co. and Wells Fargo Securities, LLC valued at combined public offering price of $2.25 (effective 2026-05-26).

Action: entry
Agreement: underwriting
Counterparty: Cantor Fitzgerald & Co. and Wells Fargo Securities, LLC
Value: combined public offering price of $2.25
Effective: 2026-05-26

Exact text from the filing

On May 26, 2026, Editas Medicine, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Cantor Fitzgerald & Co. and Wells Fargo Securities, LLC as representatives of the underwriters named therein (the “Underwriters”), relating to an underwritten public offering of 55,555,556 shares

View on SEC.gov

Browse all material agreements →

Editas Medicine, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-066317

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.